Although the significance of LDHB in cancers is still inadequate and elusive, several studies have indicated its critical role in tumor development, and LDHB have been identified as potential therapeutic targets for the treatment of malignant tumors.22 LDHB can also be used as a metabolic marker of response to neoadjuvant chemotherapy in breast cancer.17 Meanwhile, restored expression of LDHB repressed cell proliferation, invasion, and migration in pancreatic cancer.18 Thus, demethylating agents might be a promising new therapeutic strategy for prostate and pancreatic cancer. The gene discussed is LDHB; the disease is breast cancer.